Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood Cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4,317 result(s) found for: Blood Cell. Displaying page 1 of 216.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-004225-22 Sponsor Protocol Number: CSEG101A2401B Start Date*: 2021-05-03
    Sponsor Name:Novartis Pharma AG
    Full Title: An Open-label, Multi-center, Phase IV, Rollover Study for Patients with Sickle Cell Disease who have Completed a Prior Novartis-Sponsored Crizanlizumab Study
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    20.1 10010331 - Congenital, familial and genetic disorders 10002077 Anaemia sickle cell LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) IT (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004568-37 Sponsor Protocol Number: INV543 Start Date*: 2018-11-30
    Sponsor Name:Nova Laboratories Limited
    Full Title: A prospective open label, pharmacokinetic study of an oral hydroxyurea solution in children with sickle cell anemia
    Medical condition: Sickle Cell Anaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004045-25 Sponsor Protocol Number: GBT440-034 Start Date*: 2018-04-17
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: An Open Label Extension Study of Voxelotor (GBT440) Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005889-40 Sponsor Protocol Number: ABR-15108 Start Date*: 2007-08-14
    Sponsor Name:Academic Medical Centre
    Full Title: N-Acetylcysteine for Treatment of Sickle Cell Disease
    Medical condition: Patients homozygous for sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040644 Sickle cell disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003601-66 Sponsor Protocol Number: CSEG101ANL01T Start Date*: 2021-07-14
    Sponsor Name:Amsterdam UMC - AMC
    Full Title: The Effect of Crizanlizumab on Cerebral Perfusion and Oxygenation in Sickle Cell Patients
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001585-36 Sponsor Protocol Number: AMC_SMILE_1.0 Start Date*: Information not available in EudraCT
    Sponsor Name:Amsterdam UMC
    Full Title: EffectS of L-glutaMIne on oxIdative stress, sickLE erythrocyte viability, inflammation and endothelial activity in sickle cell disease (SMILE trial)
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001351-13 Sponsor Protocol Number: APHP201133 Start Date*: 2021-11-26
    Sponsor Name:Assistance Publique des Hôpitaux de Paris(AP-HP)
    Full Title: Interest of famotidine in reducing endothelial expression of P-selectin in children with sickle cell disease: pilot study, single-center, prospective, non-comparative
    Medical condition: major sickle cell syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005161-20 Sponsor Protocol Number: SCC01 Start Date*: 2012-02-14
    Sponsor Name:University College Dublin Clinical Research Centre
    Full Title: A Randomised Controlled Double-Blind Trial of Intranasal Fentanyl versus Intravenous Morphine in the Emergency Department Treatment of Severe Painful Sickle Cell Crises in Children
    Medical condition: Severe Painful Sickle Cell Disease Crises in Children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005289-32 Sponsor Protocol Number: GBT2104-133 Start Date*: 2021-11-10
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001838-34 Sponsor Protocol Number: GBT440-029 Start Date*: 2019-11-05
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients with Sickle Cell Disease
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-003573-41 Sponsor Protocol Number: 1101-202 Start Date*: 2009-01-15
    Sponsor Name:TRF Pharma, Inc.
    Full Title: A randomised, double-blind, placebo-controlled study to assess the safety and activity of TRF-1101 on microvascular blood flow, vascular endothelial injury, and vasoocclusive pain in patients with ...
    Medical condition: Sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040644 Sickle cell disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004209-15 Sponsor Protocol Number: GBT440-007 Start Date*: 2019-01-08
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants with Sickle Cell Disease
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-003485-39 Sponsor Protocol Number: NN7533-4470 Start Date*: 2022-07-19
    Sponsor Name:Novo Nordisk A/S
    Full Title: A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease
    Medical condition: Sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022812-37 Sponsor Protocol Number: ORH/PID/6265 Start Date*: 2011-06-07
    Sponsor Name:Oxford University Hospitals NHS Trust
    Full Title: A phase 2 trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
    Medical condition: Diffuse Large B-cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003144-76 Sponsor Protocol Number: GBT440-038 Start Date*: 2020-01-10
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: An Open-Label Extension Study of Voxelotor Administered Orally to Pediatric Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-023040-32 Sponsor Protocol Number: ROMI-ADVM-004 Start Date*: 2011-05-05
    Sponsor Name:Celgene Corporation
    Full Title: A phase IV, Open-Label, Single-Arm ROLLOVER STUDY FOR SUBJECTS WHO PARTICIPATED IN OTHER ROMIDEPSIN PROTOCOLS. Estudio de extensión de fase IV, abierto, de un solo brazo para pacientes que hayan p...
    Medical condition: Rollover study supporting all indications from prior Romidepsin protocols eligible for participation in this study. Estudio de extensión que recoge todas las indicaciones de protocolos anteriores d...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001414 Adult T-cell lymphomas/leukaemias HLT
    12.1 10042971 T-cell lymphoma LLT
    12.1 10042979 T-cell lymphoma recurrent LLT
    12.1 10042980 T-cell lymphoma refractory LLT
    12.1 10042981 T-cell lymphoma stage I LLT
    12.1 10042982 T-cell lymphoma stage II LLT
    12.1 10042983 T-cell lymphoma stage III LLT
    12.1 10042984 T-cell lymphoma stage IV LLT
    12.1 10002450 Angioimmunoblastic T-cell lymphomas HLT
    12.1 10022704 Intestinal T-cell lymphomas HLT
    12.1 10034622 Peripheral T-cell lymphomas NEC HLT
    12.1 10042988 T-cell unclassifiable lymphomas HLT
    12.1 10001414 Adult T-cell lymphomas/leukaemias HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005371-16 Sponsor Protocol Number: D4302C00001 Start Date*: 2012-07-30
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Medical condition: Diffuse Large B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002605-62 Sponsor Protocol Number: BCC1801 Start Date*: 2018-10-23
    Sponsor Name:Herlev and Gentofte Hospital
    Full Title: Phase IIa trial with PD-L1 IO103 vaccination with montanide in patients with basal cell carcinoma.
    Medical condition: basal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007286 Carcinoma basal cell LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000932-70 Sponsor Protocol Number: APHP200067 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE -HOPITAUX DE PARIS
    Full Title: Randomized prospective trial evaluating the efficacy of the antiCD38 monoclonal antibody isatuximab in the treatment of PCRA by major ABO mismatch after allogeneic hematopoietic stem cell transplan...
    Medical condition: Pure cell red aplasia by major ABO mismatch after allogeneic hematopoietic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002965 Aplasia pure red cell PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021165-76 Sponsor Protocol Number: LU2006 Start Date*: 2011-09-19
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: STOMP: Small cell lung cancer Trial of Olaparib (AZD2281) as Maintenance Programme: a randomised, double blind, multicentre phase II trial
    Medical condition: Small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10041071 Small cell lung cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 18 19:34:58 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA